2/9/2010

Teva Pharmaceutical Industries expanded a deal with Active Biotech for multiple sclerosis drug laquinimod to include distribution rights in the Nordic and Baltic regions. The companies are conducting global late-stage trials of the once-daily oral treatment in patients with relapsing-remitting multiple sclerosis.

Full Story:
MarketWatch

Related Summaries